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introduction
Based on randomized trials and meta-analyses the – albeit
limited – benefit of first-line chemotherapy for fit patients
with advanced and metastatic non-small cell lung cancer has
been firmly established. The concomitant or sequential
chemotherapy and radiotherapy for patients with locally
advanced but inoperable tumors (Stage IIIB) has become the
recommended treatment for patients with a good performance
status and there is compelling evidence that patients with
operated stage IB to IIIA disease may benefit from adjuvant
chemotherapy. As a consequence, today most patients with non-
small cell lung cancer will receive some form of chemotherapy at
the time of diagnosis and – since all patients with advanced
disease and a proportion of patients with localized disease
at presentation will experience tumor relapse, many of them
in good general condition – the question of second-line
chemotherapy will be encountered with increasing frequency.
Considering the literature of patients treated with second-line
chemotherapy, one has to be aware of the heterogeneity of
the patient population. While the selection criteria of most
trials require a performance status of 0 to 2 and patients with
co-morbidity are excluded, the patients may still be quite
heterogeneous since the indication of first-line chemotherapy
may range from combined modality therapy for locally
advanced disease to metastatic disease. Second-line
chemotherapy for patients who received adjuvant chemotherapy
will certainly become an issue in the near future.
For patients initially treated for advanced disease,
a distinction has to be made between patients with primary
refractory tumors and patients with relapse after response to
first-line treatment. While in other tumors types such as in
malignant lymphoma, there is a consensus how these groups of
patients are defined no such consensus has yet been established
for non-small cell lung cancer. The recommended first-line
chemotherapy for fit patients with non-small cell lung cancer is
a platinum-based two-drug combination. However, this
continues to be a matter of debate and some patients are
treated upfront with non-platinum combinations which
increases the heterogeneity of patients considered for second-
line treatment.
Given the recent results of epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors, patients with non-small cell
lung cancer cannot be considered as one group in relation to
systemic therapy. Increasingly, clinical and molecular
characteristics will also be used to identify patients who might
benefit from a certain form of treatment.
second-line chemotherapy for patients
with advanced non-small cell lung
cancer
survival advantage of docetaxel versus best
supportive care
The database demonstrating a survival advantage of second-line
chemotherapy compared to best supportive care is small. It
originates from one landmark study at the National Cancer
Institute of Canada comparing the use of docetaxel given every
three weeks to best supportive care alone in patients with stage
IIIB and IV non-small cell lung cancer after cisplatin-based
first-line chemotherapy [1]. Requirements were a performance
status of 0 to 2 and no symptomatic or uncontrolled brain
metastasis. The trial included patients with response, no change
and progressive disease during cisplatinum treatment. The dose
of docetaxel was reduced from 100 mg/m2 to 75 mg/m2 after the
identification of a high toxic death rate in the chemotherapy
arm during interim safety monitoring. The median survival of
the chemotherapy group was 7.0 months versus 4.6 months in
the control group (log rank P = 0.047). The response rate for
patients with measurable disease was 7.1%. There were no toxic
deaths with the dose of 75 mg/m2 and only one of 55 patients
developed febrile neutropenia. Quality-of-life (QoL) was
evaluated in this trial using the Lung Cancer Symptom Scale and
the European Organisation for Research and Treatment
(EORTC) quality-of-life questionnaire (QLQ–C30). Significant
differences between the two arms favoring docetaxel were
detected for pain scores and in the deterioration of the global
QoL today score [2].
The cost-effectiveness of second-line docetaxel chemotherapy
at 75 mg/m2 has been estimated in two studies. Based on the
perspective of the Canada’s public health system the cost was
$31 776 per life-year gained [3]. Viewed from the perspective of
the United Kingdom National Health System (NHS) the cost
per life-year gained was estimated to be £13 863 [4].
randomized studies comparing three-weekly
docetaxel with other agents in second-line
chemotherapy. Pemetrexed is an alternative
There are currently two phase III trials published comparing
docetaxel chemotherapy at 75 mg/m2 with other agents in
second-line treatment. A phase III trial compared docetaxel at
100 mg/m2 and 75 mg/m2 with a control arm of either weekly
vinorelbine or 3-weekly ifosfamide [5]. Response was 10.8% and
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6.7% in the docetaxel arms and 0.8% in the control arm. Median
survival in all treatment arms ranged between 5.5 and 5.7
months and there was no significant advantage in median
survival for docetaxel at either dose and the major endpoint
of superiority of docetaxel was not reached. However, the one-
year survival was 21% with docetaxel 100 mg/m2, 39% with
docetaxel 75 mg/m2 and 19% only in the control group
(P = 0.025). Examining response rates by the stratification
factors prior docetaxel, best response to platinum and
performance status did identify significant correlations.
A phase II study of the multi-targeted antifolate pemetrexed
in patients who progressed during or within 3 months after first-
line chemotherapy showed a response rate of 8.9% and a median
survival of 5.7 months [6]. This prompted a comparative
phase III study of three weekly pemetrexed at 500 mg/m2 versus
docetaxel 75 mg/m2 based on a non-inferiority design [7]. While
there was no difference in response rates of 9.1% and 8.8% and
median survival times of 8.3 months and 7.9 months,
respectively, there was a difference in the toxicity profile with
lower rates of neutropenic fever, neutropenic infections,
hospitalization due to drug-related side effects, use of
granulocyte colony stimulating factor and alopecia in favor of
pemetrexed. Thus docetaxel and pemetrexed have comparable
efficacy in second-line therapy of non-small cell lung cancer
with a toxicity profile favoring pemetrexed.
is there an advantage for weekly docetaxel?
One randomized phase II trial and two randomized phase III
trials compared weekly docetaxel 40 mg/m2 with the standard
3-weekly schedule of docetaxel at 75 mg/m2. The randomized
phase II trial showed similar response rates of 3.2% versus 4.8%
and median survival times of 5.5 months versus 5.8 months
in the weekly as compared to the 3-weekly arm. Febrile
neutropenia was not encountered in the weekly arm, while it
was documented in 6.5% of patients in the 3-weekly arm [8].
The major endpoint of the first phase III study comparing
weekly docetaxel at 33 mg/m2 with the standard 3-weekly arm
was QoL at 3 weeks [9]. No differences were observed in global
QoL scores. However there was a statistical significant difference
favoring weekly docetaxel in regard to hair loss, pain and cough,
and a significant difference favoring 3-weekly docetaxel in
relation to diarrhea. Survival was the major endpoint of the
second phase III study comparing weekly docetaxel at 35 mg/m2
with the 3-weekly arm [10]. Response rates were similar with
10.5% versus 12.6% while the median survival times of 9.2
months versus 6.3 months showed a trend favoring the weekly
docetaxel arm. There was significantly less hematological
toxicity in the weekly arm. Based on these studies, docetaxel
given weekly has similar efficacy as the conventional 3-weekly
schedule but slightly better control of pain and cough and
potentially slightly less hematological toxicity. In the selection
between these regimens, ease of access to ambulatory care and
patient preference remain decision factors.
activity of other single agents
An extensive review on second-line chemotherapy for advanced
non-small cell lung cancer has recently been published which
outlines the results of the many phase II trials [11]. Paclitaxel
weekly at 80 mg/m2 has been examined side to side with
docetaxel weekly at 36 mg/m2 in a small randomized phase II
study in patients with prior cisplatin therapy [12]. Median
survival was 3.2 months with paclitaxel and 6 months with
docetaxel. However, the study was too small to allow definite
conclusions. The lack of efficacy of paclitaxel in the second-line
setting was also reported from a large phase II study with
a response rate of 3% and a median survival of 4.5 months [13].
Two of the three reports with vinorelbine, given weekly as
second-line treatment, reported no responses, suggesting that
this drug does not have major activity in this setting. This is
supported by the study of Fossella, in which the response rate in
the control arm of vinorelbline or ifosfamide was 0.8% only [5].
Gemcitabine has been examined in second-line treatment in
three phase II studies [14–16]. Response rates ranged between
6 and 20% and median survival times between 3.9 and 7.8
months, suggesting that this agent might be active in this setting.
combination or single agent in second-line
treatment?
Only randomized studies will be able to answer the question
whether combination chemotherapy would result in a better
outcome than single agent therapy. Studies available so far all
document increased toxicity for the combination without
improvement of survival or QoL.
Two studies compared the results of 3-weekly docetaxel with
or without the addition of irinotecan and found significantly
increased gastrointestinal toxicity with the combination [17, 18].
Another study examined cisplatin with or without irinotecan
in patients pretreated with gemcitabine and docetaxel [19].
While the response rate was 22.5% for the combination versus
7% for cisplatin alone, there was no difference in survival and
QoL measurements, but significantly more febrile neutropenia
with the combination.
The toxicity of a combination of weekly docetaxel and
vinorelbine has been shown in another study comparing this
combination with weekly docetaxel and gemcitabine in second-
line treatment [20]. The vinorelbine arm had to be terminated
early because of neutropenic fever in 70% of the patients. The
combination of docetaxel and gemcitabine was better tolerated.
However, neither response nor survival was better than with
single agent treatment. For the time being, combination
chemotherapy in second-line treatment remains experimental
and is not recommended outside clinical trials.
characteristics of patients treated with
second-line therapy
Based on the selection criteria in clinical studies, patients in
studies with second-line therapy of non-small cell lung cancer
are certainly not representative of all patients, for whom the
question of further therapy arises. A recent study examined
which of the patients with stage IIIB or IV non-small cell lung
cancer who participated in a phase III trial of paclitaxel and
carboplatin were likely to receive second-line treatment [21].
Forty-four percent of patients were treated with second-line
chemotherapy and multivariate analysis showed higher baseline
performance status, female sex, non-squamous cell histology
and having received two or more cycles of chemotherapy to be
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associated with second-line chemotherapy, while early
termination of first-line chemotherapy decreased the likelihood
of further therapy. Another retrospective analysis examined
the outcome in 43 patients who had received more than two
prior chemotherapy regimens [22]. Response rates were
reported for 21% of these patients in first-line, for 16% in
second-line, 2% in third-line and 0% in fourth-line. The
median survival from the start of the last – either third or
fourth – treatment was 4 months.
new therapeutic approaches targeting
the epidermal growth factor receptor
The effect of orally administered EGFR tyrosine kinase
inhibitors has shifted the attention of patients and physicians to
the potential of molecular therapies for second-line treatment of
non-small cell lung cancer. The reports of two large phase II
trials on the activity of gefitinib at two dose levels in patients
with cisplatin-pretreated non-small cell lung cancer raised the
hope for the possibility of a new therapeutic approach beyond
conventional chemotherapy [23, 24]. An unexpected response
rate of 10 to 20% was documented in patients heavily pretreated
with chemotherapy, and symptom improvement was seen in
43% of patients at a daily dose of 250 mg. Side effects were mild
and included skin rash and diarrhea. Because of similar response
rates at 500 mg and 250 mg, but increased toxicity at the higher
dose level, a dose of 250 mg was chosen for further studies.
Clinical parameters associated with response were female sex,
never smokers, adenocarcinoma, and Japanese origin.
A similar phase II study with erlotinib at a daily dose of
150 mg also demonstrated a response rate of 12% and a
possible association of survival and the development of skin
rash was reported [25].
Both agents were subsequently examined in placebo-
controlled randomized phase III studies in patients with non-
small cell lung cancer pretreated with one or two chemotherapy
regimens with the aim to detect a 33% improvement in survival
[26, 27]. This was reached in the erlotinib study with median
survival times of 6.7 months versus 4.7 months (hazard ratio
0.7, 95% confidence interval (CI) 0.58–0.85), but just missed in
the gefitinib study with median survival times of 5.6 months
versus 5.1 months (hazard ratio 0.89, 95% CI 0.77–1.02).
Response rates were 8.9% in the erlotinib and 8% in the gefitinib
study. In the erlotinib study multiple regression analysis
identified a history of never smoking and the presence of
adenocarcinoma (as well as EGFR expression with data available
only in 43% of patients) with response. Longer survival was
associated with erlotinib treatment, Asian ethnicity,
adenocarcinoma and a history of never smoking. In the gefitinib
study a pre-planned subgroup analysis demonstrated a survival
advantage for gefitinib in never smokers and patients of
Asian origin.
The discovery of mutations in the EGFR in patients with
a dramatic tumor response to gefitinib not only pointed to
a new molecular entity of non-small lung cancer, but has also
raised the hope of identifying patients with a high likelihood of
response and benefit from a systemic treatment based on
a laboratory analysis [28, 29]. Mutations of the EGFR involve
deletion mutations in exon 19 in about half of the patients,
missense mutations in exon 21 in about 40% and mutations in
exon 10 and 20 in about 10% of patients [30, 31]. The rate of
patients with mutations is about 10% in Europe and North
America and 30% in Asian countries. Mutations are associated
with adenocarcinoma, female sex, and a history of non-
smoking. Response to gefitinib or erlotinib is associated with the
presence of these mutations.
More recently, amplification of the EGFR gene has also
been associated with response to gefitinib [32]. Molecular
examinations of tumors from patients participating in the
erlotinib versus placebo trial confirmed the association of
EGFR mutations with response and identified the association
of EGFR amplication with survival [33].
Which of the molecular test or combination of tests
ultimately will best serve to identify patients with tumor
sensitive to therapy cannot be conclusively stated yet.
Given the results of these phase III studies and numerous
phase II studies it is irrefutable that EGFR tyrosine kinase
inhibitors are active and provide symptom improvement in
patients with chemotherapy pretreated non-small cell lung
cancer. The major question, which needs to be addressed now, is
to whom such a treatment should be offered. While there are
advocates for the general use of these agents in second-line lung
cancer, many feel that patients should be selected based on
clinical features or molecular characteristics. Whether the
treatment outcome for patients selected on the basis of
a molecular study would be superior to the selection based on
clinical characteristics remains to be determined.
Advances in this field over the past 3 years have been rapid,
and other agents, including other tyrosine kinase inhibitors and
monoclonal antibodies are being investigated in second-line
treatment of patients with non-small cell lung cancer. With
better knowledge about the interaction between inhibitors and
mutated receptor, agents might be identified which provide
a response in patients developing resistance to gefitinib or
erlotinib [34]. Although EGFR antibodies are being examined as
single agent or in combination for second-line treatment of
non-small cell lung cancer, definitive results have not yet been
published [35].
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